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Allogenic SCT/DLI are promising T-cell based therapies
to cure AML-pts. Antileukaemic T-cell-reactivity has to
be improved/re-established in pts in vivo. Ex vivo
leukaemia-derived DC (DCleu) are the most effective
antileukaemic T-cell-stimulators.
Aim and methods
We generated DCleu ex vivo from AML blasts from
heparinised whole blood (‘WB-DC’, to simulate the in
vivo situation) from 65 AML-pts in active stages of the
disease using standard methods ( ‘Picibanil’, ‘MCM-
Mimic’, ‘Ca-ionophore’, ‘IFNa’) or 11 minimalised cock-
tails (‘WB-minicock-DC’, combinations of 1-3 selected
cytokines, antibiotics, bacterial lysates, or other clinically
approved response-modifiers) and to correlate propor-
tions of DC- or T cellsubsets and cytokine profiles with
results with their ex vivo stimulatory capacity for antileu-
kaemic T-cells and the pts’ response to immunotherapy
(SCT/DLI).
Results
1. Generation of DC: we could identify 4 of 11 mini-
cocks, that allowed the generation of DC/DCleu from
blast-containing WB-samples with at least one of the
three methods. Some of the cocktails induced ex vivo
blast-proliferation in individual pts. Proportions of
DC-subtypes (e.g DC/DCleu/mature DC) were compar-
able to proportions generated with standard DC meth-
ods. 2. Antileukaemic functionality: In 21 cases T-cells
stimulated with 1 to 3 ‘WB-minicock-DC’ resulted in
56% cases with blast-lysis; in 6 pts 2-3 cocktails could
be studied in parallel and in at least one of the cocktails
a blastlysis could be achieved. Blast lysis (vs non-lysis)
correlated with higher proportions of DC-subtypes: (DC,
DCleu blastconversion to DCleu), higher proportions of
T-cell-subtypes (viable, CD8 Tcells), higher concentra-
tions of IL-12 and IFNg but lower concentrations of
IL-6 and IL-8 3.Clinical correlation: AML-pts success-
fully responding to immunotherapy (SCT or DLI ther-
apy) presented with higher proportions of DC, DCleu
and CCR7+mature DC compared to pts without success-
ful immunotherapy.
Conclusion
DC/DCleu can be generated regularly from MNC or WB
and with at least 1 to 4 of 11 minicocks containing combi-
nations of 1-3 selected, clinically approved response modi-
fiers. T-cells stimulated with ‘WB-minicock-DC’ achieved
antileukaemic function, although not with every cocktail.
A patient-individual testing of the best cocktail as well as
the achieved antileukaemic (ex vivo) function can contri-
bute to define cocktails of responsemodifieres to be appli-
cated to AML pts to achieve or sustain remission.
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